LYSOGENE Logo

LYSOGENE

A former clinical-stage biotech that developed gene therapies for rare CNS diseases.

LYS | PA

Overview

Corporate Details

ISIN(s):
FR0013233475
LEI:
969500T64RILK1RD0852
Country:
France
Address:
18 RUE JACQUES DULUD, 92200 NEUILLY-SUR-SEINE

Description

Lysogene was a clinical-stage biotechnology company that specialized in the research and development of gene therapies for rare, inherited neurodegenerative diseases affecting the central nervous system (CNS). The company's approach focused on delivering a functional copy of a deficient gene directly to the brain to address the root cause of the targeted disorder. Its pipeline included investigational treatments for lysosomal storage diseases such as Sanfilippo syndrome type A (MPS IIIA) and GM1 gangliosidosis. Following clinical and financial challenges, the company initiated judicial liquidation proceedings in 2023.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-05-26 17:32
Informations privilégiées / Autres communiqués
French 84.9 KB
2023-05-26 17:32
Inside Information / Other news releases
English 83.2 KB
2023-05-26 10:00
Informations privilégiées / Autres communiqués
French 85.6 KB
2023-05-26 10:00
Inside Information / Other news releases
English 83.5 KB
2023-05-15 18:00
Inside Information / Other news releases
English 83.5 KB
2023-05-15 18:00
Informations privilégiées / Autres communiqués
French 85.6 KB
2023-04-29 18:00
Inside Information / News release on accounts, results
English 82.9 KB
2023-04-29 18:00
Informations privilégiées / Communiqué sur comptes, résultats
French 85.1 KB
2023-04-14 18:00
Inside Information / Other news releases
English 83.2 KB
2023-04-14 18:00
Informations privilégiées / Autres communiqués
French 85.4 KB
2023-03-24 20:00
Informations privilégiées / Autres communiqués
French 95.8 KB
2023-03-24 20:00
Inside Information / Other news releases
English 93.5 KB
2023-02-16 18:00
Inside Information / Other news releases
English 107.8 KB
2023-02-16 18:00
Informations privilégiées / Autres communiqués
French 110.2 KB
2023-02-03 18:00
Informations privilégiées / Autres communiqués
French 91.3 KB

Automate Your Workflow. Get a real-time feed of all LYSOGENE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for LYSOGENE

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for LYSOGENE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.